The 20 patients were favorable-risk AML categorized by genetics, of which 3 patients were t(8;21)(q22;q22.1); RUNX1-RUNX1T1, 3 patients were inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, 5 patients were biallelic mutated CEBPA, and 9 patients were normal karyotype with mutated NPM1 without FLT3-ITD. This evidence concerns the gene CEBPA and acute myeloid leukemia.